Хайлтын үр дүнгүүд - Filip Janků

Үр дүнг сайжруулах
  1. 1
    Tumor heterogeneity in the clinic: is it a real problem?

    Tumor heterogeneity in the clinic: is it a real problem? -н Filip Janků

    Хэвлэсэн 2013
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

    Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients -н Filip Janků

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

    Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? -н Jiří Polívka, Martin Pešta, Filip Janků

    Хэвлэсэн 2015
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)

    Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) -н Hazem El‐Osta, Filip Janků, Razelle Kurzrock

    Хэвлэсэн 2010
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

    Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening -н Jacob J. Adashek, Filip Janků, Razelle Kurzrock

    Хэвлэсэн 2021
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Erdheim-Chester Disease: Characteristics and Management

    Erdheim-Chester Disease: Characteristics and Management -н Javier Muñoz, Filip Janků, Philip R. Cohen, Razelle Kurzrock

    Хэвлэсэн 2014
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia

    STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia -н Javier Muñoz, Navjot Dhillon, Filip Janků, Stephanie S. Watowich, David S. Hong

    Хэвлэсэн 2014
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    The mu opioid receptor: A new target for cancer therapy?

    The mu opioid receptor: A new target for cancer therapy? -н Patrick A. Singleton, Jonathan Moss, Daniel D. Karp, Johnique T. Atkins, Filip Janků

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    Novel Therapeutic Targets in Non-small Cell Lung Cancer

    Novel Therapeutic Targets in Non-small Cell Lung Cancer -н Filip Janků, Ignacio Garrido‐Laguna, Luboš Petruželka, David J. Stewart, Razelle Kurzrock

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

    Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing -н Filip Janků, Ahmed O. Kaseb, Apostolia M. Tsimberidou, Robert A. Wolff, Razelle Kurzrock

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer

    Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer -н Filip Janku, Lorraine Johnson, Daniel D. Karp, Johnique T. Atkins, Patrick A. Singleton, J. Moss

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes

    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes -н Filip Janků, Hesham M. Amin, Dan Yang, Ignacio Garrido‐Laguna, Jonathan C. Trent, Razelle Kurzrock

    Хэвлэсэн 2010
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    ALK fusions in the pan-cancer setting: another tumor-agnostic target?

    ALK fusions in the pan-cancer setting: another tumor-agnostic target? -н Aditya Shreenivas, Filip Janků, Mohamed A. Gouda, Hui‐Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    Challenges and perspective of drug repurposing strategies in early phase clinical trials

    Challenges and perspective of drug repurposing strategies in early phase clinical trials -н Shumei Kato, Stacy L. Moulder, Naoto T. Ueno, Jennifer J. Wheler, Funda Meric‐Bernstam, Razelle Kurzrock, Filip Janků

    Хэвлэсэн 2015
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

    BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes -н Hazem El‐Osta, Gerald S. Falchook, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Kevin Kim, Sijin Wen, Filip Janků, Razelle Kurzrock

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center -н Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers -н Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  18. 18
    A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies

    A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies -н John W. Moroney, Matthew Schlumbrecht, Thorunn Helgason, Robert L. Coleman, Stacy Moulder, Aung Naing, Diane C. Bodurka, Filip Janků, David S. Hong, Razelle Kurzrock

    Хэвлэсэн 2011
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  19. 19
    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors -н Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    Хэвлэсэн 2012
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  20. 20
    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors -н Jennifer J. Wheler, Johnique T. Atkins, Filip Janků, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda Meric‐Bernstam

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: